Department of Emergency Medicine, University of Michigan, Ann Arbor, USA.
Acad Emerg Med. 2012 Apr;19(4):448-54. doi: 10.1111/j.1553-2712.2012.01328.x.
Clinical trials investigating therapies for acutely and critically ill and injured patients in the earliest phases of treatment often can only be performed under regulations allowing for exception from informed consent (EFIC) for emergency research. Implementation of these regulations in multicenter clinical trials involves special challenges and opportunities. The Rapid Anticonvulsant Medication Prior to Arrival Trial (RAMPART), the first EFIC trial conducted by the Neurological Emergencies Treatment Trials (NETT) network, combined centralized resources and coordination with retention of local control and flexibility to facilitate compliance with the EFIC regulations. Specific methods used by the NETT included common tools for community consultation and public disclosure, sharing of experiences and knowledge, and reporting of aggregate results. Tracking of community consultation and public disclosure activities and feedback facilitates empirical research on EFIC methods in the network and supports quality improvements for future NETT trials. The NETT model used in RAMPART demonstrates how EFIC may be effectively performed in established clinical trial networks.
在治疗的最早阶段,对急性和危重病及创伤患者进行治疗的临床试验通常只能在允许对紧急研究豁免知情同意的规定下进行。在多中心临床试验中实施这些规定涉及特殊的挑战和机遇。快速抗惊厥药物到达前试验(RAMPART)是由神经急症治疗试验(NETT)网络进行的第一个豁免知情同意的试验,该试验结合了集中资源和协调,同时保留了对当地控制的保留和灵活性,以方便遵守豁免知情同意的规定。NETT 使用的具体方法包括社区咨询和公众披露的通用工具、经验和知识的共享,以及汇总结果的报告。跟踪社区咨询和公众披露活动以及反馈,有助于对网络中豁免知情同意方法进行实证研究,并支持未来 NETT 试验的质量改进。RAMPART 中使用的 NETT 模式展示了如何在既定的临床试验网络中有效地实施豁免知情同意。